Synaptic adhesion molecules play an important role in the formation, maintenance and refinement of neuronal connectivity. Recently, several leucine rich repeat (LRR) domain containing neuronal adhesion molecules have been characterized including netrin G-ligands, SLITRKs and the synaptic adhesion-like molecules (SALMs). Dysregulation of these adhesion molecules have been genetically and functionally linked to various neurological disorders. Here we investigated the molecular structure and mechanism of ligand interactions for the postsynaptic SALM3 adhesion protein with its presynaptic ligand, receptor protein tyrosine phosphatase s (PTPs). We solved the crystal structure of the dimerized leucine rich repeat (LRR) domain of SALM3, revealing the conserved structural features and mechanism of dimerization. Furthermore, we determined the complex structure of SALM3 with PTPs using small angle X-ray scattering, revealing a 2:2 complex similar to that observed for SALM5. Solution studies unraveled additional flexibility for the complex structure, but validated the uniform mode of action for SALM3 and SALM5 to promote synapse formation. The relevance of the key interface residues was further confirmed by mutational analysis with cellular binding assays and artificial synapse formation assays. Collectively, our results suggest that SALM3 dimerization is a pre-requisite for the SALM3-PTPs complex to exert synaptogenic activity.
Introduction
Neurons form highly complex networks of specific connection patterns through the cellular junctions at synapses. Synaptic adhesion molecules are emerging synapse organizers, which are localized at the nerve cell membranes at the synaptic cleft, and play a crucial role in the formation, maintenance and refinement of neural circuits 1 . Several families of synaptic adhesion molecules have been identified, including e.g. neurexins 2 , neuroligins 3 , synaptic adhesion like molecules (SALMs) 4 , leucine-rich repeat (LRR) transmembrane neuronal proteins (LRRTMs) 5 , leukocyte common antigenrelated receptor protein tyrosine phosphatases (LAR-RPTPs) 6 and netrin-G ligands (NGLs) 7 . The dysfunction of synaptic adhesion molecules have been proposed to be involved in onset and progression of various neurological disorders, which includes autism spectrum disorders, schizophrenia and Alzheimer's disease [8] [9] [10] [11] .
The SALM family of proteins also known as LRR and fibronectin III domain containing proteins (LRFNs), represent a family of LRR-containing synaptic adhesion molecules, with five known members (SALM1-SALM5) 4 . All the SALM proteins share a similar domain architecture consisting of an extracellular region with an LRR domain, an immunoglobulin (Ig) domain and a fibronectin III (FnIII) domain followed by a transmembrane domain (TM) and a non-structured cytoplasmic region 12 . Notably, SALM1-3 contain type I PDZ binding motifs, which are absent in SALM4 and SALM5 4, 12 (Fig. 1a ).
SALMs are considered to be postsynaptic adhesion proteins, mostly expressed in the neurons and regulate neurite outgrowth and branching 12 . In addition, they have been implicated in the regulation and development of synapse formation [12] [13] [14] . SALM3 and SALM5 possess synaptogenic activity, and promote both excitatory and inhibitory presynaptic differentiation in contacting axons 15 via trans-synaptic interaction with LAR-RPTPs 13, 14 . SALM4 suppresses excitatory synapse development by cis-inhibiting trans-synaptic SALM3-LAR-RPTP adhesion 16 . Crystal structures of human SALM5-PTPd, and also SALM2-PTPd complexes reveal 2:2 heterotetrameric trans-synaptic association between the proteins 17, 18 . We previously reported the crystal structure of mouse SALM5 LRR-Ig domain fragment, and solution structures of SALM3 and SALM5 extracellular regions 19 .
This study revealed that LRR domains of SALM5 are involved in dimerization, and the different structures indicated that overall structural features are conserved between SALM2, SALM3 and SALM5 19 . However, structural details of SALM family beyond SALM2 and SALM5 remain to be determined including SALM3 and the molecular details of its interaction with LAR-RPTPs.
SALM3 is expressed early during embryonic stage in the brain, whereas the other SALMs are expressed from the embryonic stage, and the expression is maintained or increased after birth 20 . In vivo studies using SALM3 knockout (SALM3 −/− ) mice displayed markedly reduced excitatory synapse number and locomotor activity, and exhibit behavioral hypoactivity, which underlines the importance of SALM3 in excitatory synapse development 14 . SALM3 interacts with all three known members of LAR-RPTPs (LAR, PTPs and PTPd) to induce presynaptic differentiation 14 . The interaction between SALM3 and LAR-RPTPs is markedly enhanced in the presence of the LAR-RPTP mini-exon B (meB) 14, 19 . Besides SALMs, LAR-RPTPs form trans-synaptic complexes with different families of postsynaptic adhesion proteins, which include NGL-3, IL1RAcP, neurotrophin receptor TrkC and the Slitrks 21 . The extracellular region of LAR-RPTPs contain three Ig domains, four to eight FnIII domains and multiple splicing variants at several sites: mini-exon A (meA) in the Ig2 domain, mini-exon B (meB) between Ig2 and Ig3 domain and mini-exon C (meC) located in the FnIII domain ( Fig. 1a) . In the cytoplasmic region, LAR-RPTPs contain two tandem tyrosine phosphatase domains 6, 21 . The Ig2 and Ig3 domains of PTPd and PTPs are involved in interaction with the LRR and Ig domains of SALM5 17, 18 .
In this study, we have solved the crystal structure of mouse SALM3 LRR domain and show that it forms a dimer that is close to identical to that of SALM5, and the residues that are involved in dimerization and their interactions are largely conserved, and our complementary biophysical studies support this. We also solved the small angle X-ray scattering (SAXS) structure of SALM3-PTPs complex that verifies the formation of the 2:2 trans-heterotetrametric complex between the proteins.
Mutational studies with a cell-based binding assay and a synapse formation assay confirm the binding mechanism of SALM3 to PTPs and the identity of the key interface residues that are largely the same as for the SALM5-PTPd interaction. Therefore, we conclude that SALM3 and SALM5 interact in similar manner with their LAR-RPTP ligands to induce presynaptic differentiation. Solution scattering studies suggest that the dimeric complex has significant conformational flexibility. Our results also confirm that dimerization is absolute requirement for induction of synapse formation by the SALM3, similar to SALM5, and thus appears to be common for the SALM family proteins involved in synapse formation.
Results and Discussion
The structure of the SALM3 LRR domain
The structure of mouse SALM3 LRR domain (Fig. 1b, c ) was solved at 2.8 Å resolution in space group P2 1 ( Table 1) . The crystals exhibited high degree of twinning, making the structure solution demanding (see methods). However, it was possible to obtain a good quality refined model once the correct space group was resolved. Four molecules, or two dimers, were present in the asymmetric unit of the crystal, one monomer had an N-glycan partly visible in electron density at Asn25 at the N-terminal end of the domain (Fig. 1c) . Overall two N-glycosylation sites are predicted to be present in SALM3 LRR domain (Asn25 and Asn70), with most of the glycans disordered in the structure, however. The LRR domain shows a typical extracellular LRR domain structure, similar to the known SALM5 LRR structure ( Supplementary Fig. S1 ) 19 , with an extend b-sheet on the concave side of the structure formed by the seven LRRs (L1-L7) ( Fig. 1b ) of variable length (22-24 residues) with consensus motif of "L 1 xxL 4 xL 6 xL 8 xxN 11 xL 13 " with aliphatic Leu or Ile residues mostly occupying positions 1, 4, 5, 6 and 13 and forming the hydrophobic core of each repeat, and the absolutely conserved Asn11 hydrogen bonding to the previous repeat. The LRR domain further contains an N-terminal LRRNT capping subdomain (residues 17-48) and an a-helical C-terminal LRRCT capping domain (residues 228-278) (Fig. 1b,c) , which are conserved in the vertebrate extracellular LRR domain family 22 . Both the LRRNT and LRRCT subdomains of SALM3 are stabilized by two disulphide bridges; in the LRRNT between Cys17-Cys27 and Cys21-Cys34, and in the LRRCT between Cys238-Cys257 and Cys240-Cys278. Cys278 also is the last residue of the whole LRR domain. A flexible loop (residues 216-227) is present between the 7 th LRR and the LRRCT, not visible in the SALM3 crystal structure (Fig. 1b, c) . The possible functional significance of this loop remains unknown, as its not involved in LAR-RPTPs recognition at least in SALM5-PTPd complex structures 17, 18 , while such an extension might be expected to have some functional significance, as e.g. in the case of platelet glycoprotein IB alpha LRR domain 23 .
Dimerization through the LRR domain is a defining feature of the SALM family
The SALM3 LRR domain forms a dimer similar to those observed for SALM5 and SALM2 crystal structures [17] [18] [19] (Fig. 1 ). It appears that the SALMs form a highly conserved dimeric structure based on the known structures of SALM2, SALM3 and SALM5 and our data on SALM1 oligomerization 19 , and the overall sequence conservation of the interface residues in the protein family ( Supplementary Fig S2, Table S1 ). The SALM3 LRR structure and dimer interface are close to identical to that of SALM5 ( Fig. 2, Supplementary Fig S1, Table S1 ) 19 . The hydrophobic interactions and hydrogen bonding networks are conserved at the interface with Gln131 and Arg107 forming hydrogen bonds across the dimer interface to Asn156 of the other monomer and vice versa (Fig. 2 , Table S1 ). The SALM3 LRR domain, like SALM5 and SALM2 forms an antiparallel side-by-side dimer, with a rather small interface with buried surface area of 1001 Å 2 . The interface consists of the "one-layer" central hydrogen bonding network ( Fig. 2) described above, and hydrophobic interactions formed by the N-and C-terminal regions (Fig. 2) . The dimer species is however very stable in solution for both SALM3 and SALM5, and also SALM1 based on our observations 19 . Monomeric species have not been observed in vitro. Here, we analysed the oligomeric state in solution for both the LRR domain and LRR-Ig construct for SALM3 by size exclusion chromatography-coupled multiangle static laser light scattering (SEC-MALLS) (Fig. 3b,c) . Both appear as dimers based on observed molecular weights of ca. 60 and 80 kDa (Fig. 3b,c) ; twice the size of molecules weights calculated from sequence (30, 9 and 40 kDa) . Thus, these measurements verified that the LRR domain is sufficient alone for stable dimer formation. Comparison of the SALM3, SALM5 as well as SALM2 dimers reveals highly similar structures with r.m.s.d. values of 0.691 and 0.758 Å for the LRR domains of SALM5 and SALM2 against SALM3 structure, respectively. Differences can be seen mainly in the conformation of the LRRNT capping region ( Supplementary Fig. S1 ). Thus, we conclude that the dimerization mechanism through the LRR domains is conserved in the family, generating a unique dimeric post-synaptic LAR-RPTP ligand, 16 . Function of SALM2 remains unclear, but it appears to be able to bind the LAR-RPTP receptors 18 , whereas the function of SALM1 appears quite different, with reported involvement in actin mediated post-synaptic neurexin clustering, and no synapse formation activity reported 28 .
The solution structure of SALM3-PTPσ complex
We have characterized the solution structure of SALM3 in complex with its PTPσ receptor, in order to understand the binding mode to the ligand for SALM3 by SAXS. Size exclusion chromatography coupled with SAXS (SEC-SAXS) was used to obtain the SAXS data on the SALM3 LRR-Ig -PTPσ Ig1-Ig3 complex to characterize the interaction between SALM3 and presynaptic PTPσ receptor. The SEC-profile of SALM3-PTPσ complex shows a single major peak, and the frames (350-365) with similar Rg-values, as calculated from the X-ray scattering intensities were selected for further analysis (Fig. 3a) . The SALM3 LRR-Ig and PTPσ Ig1-Ig3 structures were modelled based on the known crystal structures, as described in the methods. Rigid body fitting of the complex and ab initio envelope modelling were done against the obtained solution scattering data. The complex structure was modelled by rigid body fitting, constraining the LRR dimer structure and the ligand binding interface, while allowing the SALM3 LRR-Ig domain hinge region to rotate. The starting model was based on the SALM5-PTPd complex crystal structure (PDB 5XNP) 17 . The final rigid body refinement results against the SAXS data demonstrate that a 2:2 complex between SALM3
and PTPσ is formed similar to SALM5, with the noted flexibility at the LRR-Ig domain hinge region of SALM3. Both models with P1 and P2 symmetry fit the data well with C 2 -values of 1.7 and 2.5 respectively ( Fig. 3d ,e,f and Supplementary Fig. S3 ). The results suggest that allowing conformational freedom gives a better fit to the measured data. We have shown previously that the position of the Ig-domain is flexible relative to the LRR domain dimer for both SALM3 and SALM5 19 . This is the case also for the ligand bound structure in solution. The results for the complex structure indicate some flexibility or an equilibrium between different conformation states that can be modelled as presented with the SAXS data, and the 2:2 complex is not necessarily completely fixed and symmetrical in solution or in vivo. Furthermore, the ab initio calculated envelope can be fitted well with the rigid body models (Fig. 3g, h) . Consequently, both methods give a result that fit a 2:2 complex best. We further confirmed that 1:1 and 2:1 complexes do not fit to the data ( Supplementary   Fig. S3 ). Thus, we here show that SALM3 forms a complex with the presynaptic PTPs receptor with a similar mechanism to SALM5 binding to PTPd, and that we observe that the structure exhibits certain amount of flexibility that may be requirement for the molecular environment in the synaptic cleft between the two cellular membranes. Based on the SAXS data, we further validated the interaction sites in the SALM3-PTPs complex by site-directed mutagenesis and cell-based binding and heterologous synapse formation assays.
Mutational analysis of SALM3-PTPσ interface
The recent SALM5-PTPd complex crystal structures at 3.7 Å and 4.2 Å resolution showed that the LRRCT-region and Ig-domain of SALM5 interact with the Ig2 and Ig3 domains of PTPd, and the presence of meB sequence enhanced the interaction 17, 18 . We also reported in our earlier study 19 using surface plasmon resonance (SPR) that the interaction of SALM3 and PTPs is enhanced by tenfold in presence of meB.
Multiple sequence alignment of SALM3 and SALM5 sequences ( Supplementary Fig. S2 ), and the amino acid conservation plotted on the SALM3-PTPs complex model ( Fig. 4a, b, c) show that the PTPs interacting residues of SALM3 are mostly conserved in SALM3 and SALM5 in the vertebrates ( Fig. 4a; Supplementary Fig. S2 , Table S2 ). In addition, in the LRR domain dimer structure of SALM3, the concave surface shows large number of conserved residues between SALM3 and SALM5 based on sequence analysis (Fig. 4a) 19 . This might indicate a potential binding site, the ligand for which remains to be identified.
Based on the sequence analysis, and in particular the SAXS structure of SALM3-PTPs complex, we suggest that the binding interface of SALM3-PTPs is similar to SALM5-PTPd, with the observed dependence on the presence of meB 14, 19 . In order to verify this, we generated several deletion and point mutations to SALM3 extracellular domain at the SALM3-PTPs ligand interface modelled based on the binding interface interactions of SALM5-PTPd structure. Mutants were expressed in HEK293T cells, and tested for interaction with PTPs-Fc fusion protein using an in-cell western binding assay. Initially, we measured the apparent binding affinity of soluble dimeric PTPs-Fc to SALM3 on the cell surface to be 22.32 ± 5 nM (Fig. 4d) . The negative controls showed no detectable signal ( Fig. 4f) , which confirmed the specificity of the assay. To assess the effect of the point mutations, we used 150 nM PTPs-Fc .
Firstly, SALM3 DLRR, SALM3 DLRR+DFn and SALM3 DIg-Fn domain deletion mutants were expressed on the surface of HEK293T cells, but showed no interaction with PTPs (Fig. 4e) .
The cell-based binding studies on SALM3 deletion mutants verified that both the LRR and Ig-domain of SALM3 are involved and necessary for the PTPs interaction, and neither alone is enough for binding to the PTPs. Point mutations on the SALM3 LRR and Ig-domains were analysed for PTPs interaction to probe and verify more closely the importance of binding interfaces of SALM3-PTPs complex.
The binding interface in SALM3-PTPs complex is formed by three interaction sites ( Fig. 4b , Supplementary Table S2 ), similar to SALM5-PTPd (PDB 5XNP, 5XWT) 17, 18 . In site I the SALM3
LRRCT forms an interface with the Ig2-domain of PTPs, in site II SALM5 Ig-domain interacts with Ig3-domain of PTPs and in site III the SALM3 Ig-domain binds to Ig2-domain of PTPs 17 . Here, we generated mutations in SALM3 on these three sites (Fig 4b, c ) in order to validate the SALM3 complex structure.
In the case of SALM3-PTPs complex, in site I, Arg247 (SALM5 Arg253) forms hydrogen bond with the PTPs Gln202 and back bone carbonyl of Val225 (Fig. 4c ). In the cell-based binding assay SALM3 Arg247Ala mutant shows no interaction with PTPs (Fig. 4e) . This confirms its critical importance for the interaction for SALM3 with PTPs. In an earlier study 18 , it was reported that SALM5 Arg253Ala decreased the binding affinity with PTPd eight-fold compare to the wild-type (WT). The site consists of additional hydrophobic interactions by residues Pro212, Cys 246, Leu249
and Trp250 in SALM5 with PTPd, corresponding to SALM3 Pro210, Cys240, Leu243 and Trp244 residues, in equivalent positions ( Supplementary Table S2 ). Sequence analysis further confirms that the residues are highly conserved in SALM3 and SALM5 ( Supplementary Fig. S2 and Table S2 ).
Essentially all the PTPs residues involved are conserved on all three interfaces (Supplementary Fig.  S4 ).
In site II, SALM3 Arg285 (SALM5 Arg291) forms an ion pair with PTPs Asp275, and hydrogen bonds to the main chain carbonyl group on Thr277 of PTPs (Fig. 4c) . These interactions are conserved between the two complexes. However, not all interface residues in the SALM Igdomains are conserved. SALM3 Leu305 (Arg311 in SALM5) binds to a hydrophobic pocket surrounded by Met282, Tyr266 and Glu279 side chains (Fig. 4c) . This is different in SALM5 where the Arg311 hydrogen bonds to adjacent PTPd Tyr257 and backbone carbonyl groups at Glu270-Asp271. These amino acid differences at the binding site might lead to slight changes in specificity or affinity in vivo.
In addition, at site II in the SALM3 complex Leu282 (SALM5 Leu288) forms hydrophobic interactions with PTPs Met305 and the peptide main chain at the turn residues 306-307 of the PTPs Ig3-domain (Fig. 4c) . The cell-based binding assays of SALM3 Arg285Ala-Leu282Arg and Arg285Ala-Leu305Ala double mutants with PTPs showed no signal for interaction (Fig. 4e) , and thus verify the importance of site II and Arg285, Leu282 and Leu305 for PTPs binding. In previous studies SALM5 Leu288Ala mutation was reported to decrease affinity by 10-fold 18 , and SALM5 Lys309 and Arg311 when mutated to Asn and Thr to introduce an N-glycosylation site in place of Lys309 also abolished binding 17 .
In site III of the model, Glu359 (SALM5 Glu365) forms hydrogen bond with the PTPs Thr153, and a salt bridge to PTPs Lys144. SALM3 Leu321 and His313 (SALM5 Leu327 and His319) form hydrophobic interactions with Asp138, Met139 and Ala157 of PTPs (Fig. 4c) . SALM3 Thr354 is also part of the interface and packs against Leu155 of PTPs. An earlier study 17 reported that based on Ala-scanning mutagenesis that SALM5 Ser360Ala-Se329Ala double mutant (Ser360Ala equal to SALM3 Thr354) significantly reduced the interaction with LAR 18 . Our cell-based binding study showed that SALM3 Leu321Ala-His313Ala double mutation abolishes the interaction with PTPs, and SALM3 Thr354Arg-Glu359Ala double mutant decreases binding towards PTPs by ~50 % but did not abolish the interaction (Fig. 4e) . Thus, in site III the hydrophobic interactions by Leu321 and His313 appear to be most critical for the affinity in SALM3 of the residues at this interface (Fig 4c,e) and Supplementary Table S2 ). Overall, all three sites observed as binding interfaces for SALM5 appear to be functionally equivalent in SALM3, and our mutational data on the interfaces nicely complements the earlier limited mutational studies on SALM5 17, 18 .
Finally, for SALM5, it was reported that the Asn158Ala and Gln134Asn SALM5 mutations (equivalent to SALM3 residues Asn156 and Gln131) that interfere with the LRR dimerization hardly affect the binding to PTPd 18 . Our cell-based binding studies show that the SALM3 Arg107Ser-Gln131Ala mutations at the dimer interface interfere directly with PTPs binding (Fig. 4e) , which is in contrast to SALM5 results. This suggests dimerization on cell surface could be direct prerequirement for activity, at least in the case of SALM3, and potentially based on the highly similar interaction also in SALM5.
The effect of SALM3 variants on presynaptic differentiation
Since SALM3 functions as a synapse organizer inducing presynaptic differentiation through binding to presynaptic LAR-RPTPs, we tested the effect of the SALM3 mutations on presynaptic differentiation activity using heterologous synapse-formation assays. SALM3 mutants expressed in HEK293T cells were cultured with hippocampal neurons (DIV9), and the presynaptic differentiation was detected by immunostaining against the presynaptic marker synapsin I (Fig. 5) . The synaptogenic activity of SALM3 was clearly detected with the WT SALM3, but the interface mutants targeting the SALM3-PTPs interaction abolished synapsin I clustering (Fig. 5) . In addition, Thr354Arg-Glu359Ala double mutant at site III showed significantly decreased activity, despite exhibiting 50% residual binding at saturating concentration towards the PTPs-Fc (Fig. 4e) . Also the Leu282Arg mutation alone at site II was sufficient to compromise the SALM3 activity in inducing presynaptic differentiation ( Fig. 5) . In case of SALM5, it was previously reported 18 that SALM5 Arg253Ala (Site I of SALM5-PTPd complex), SALM5 Leu288Ala (Site II) and SALM5 Ile358Ala (Site III) mutants severely reduced the synaptogenic activity. In addition, the Arg107Ser-Gln131Ala SALM3 mutant that interferes with the SALM3 LRR dimerization also abolished the synaptogenic activity (Fig. 5) .
These results suggest that SALM3 mediated dimerization is critical for interaction with PTPs and the formation of SALM3-PTPs trans-synaptic signaling complex to induce presynaptic differentiation. Overall, the binding assays results are well correlated with data obtained from heterologous synapse formation analyses. This further suggests that all interactions that are important for the complex formation with PTPs are also required for the synaptogenic activity. Thus the results verify the biological significance of all the three interaction sites, and the fact that the described SALM3-PTPs interactions are necessary and sufficient for presynaptic differentiation by SALM3.
Recently Xie et. al 29 reported that LAR D1 phosphatase domains can dimerize to promote clustering and activation of synaptic differentiation. We suggest that the dimeric 2:2 complex formation by SALMs on binding to LAR-RPTPs in turn may promote the intracellular homophilic interactions of LAR-RPTPs and further activation of presynaptic differentiation.
Conclusions
SALM3 was the first protein in the SALM-family to be characterized as a ligand for presynaptic LAR-RPTPs 14 . We have now resolved its molecular mechanism of action and mode of oligomerization, which we conclude are similar with SALM5. Taken together, we conclude that dimerization might be a universal mechanism that is conserved across all SALM family proteins and that LAR-RPTP recognition occurs via the same binding interfaces. We hypothesize that SALM3 dimerization promotes presynaptic differentiation by bringing the LAR-RPTP receptors together and enhancing their clustering. Further studies are warranted to systematically test how SALM dimerization is involved in mediation of various synaptic functions and LAR-RPTP activation.
Materials and methods

Cloning, protein expression and purification.
Mouse SALM3 LRR (residues 17-284) was cloned into Drosophila pRMHA3 expression vector 30 with CD33 signal sequence at the N-terminus and a C-terminal Fc-tag preceded with a Prescission protease cleavage site. The cDNA for SALM3 was obtained from ImaGenes GmbH. The cloning and protein purification of SALM3 LRR-Ig (residues 17-367) and mouse PTPσ Ig1-3-meB + (resdiues 33-331) have been described in earlier 19 . For cell-based binding assays, the mouse SALM3 LRR-Ig-Fn (residues 17-510) and the deletion mutants SALM3 LRR (residues 17-284) "DIg-Fn", SALM3 Ig (residues 280-367) "DLRR+Fn" and SALM3 Ig-Fn (residues 280-502) "DLRR" were cloned in the pDisplay plasmid vector. The constructs contained an N-terminal HA-tag followed by the cloned SALM3 sequence, and at the C-terminus Myc-tag followed by transmembrane domain.
For mutational studies, we used site directed mutagenesis 31 to mutate the plasmid constructs of SALM3 LRR-Ig-Fn. The oligonucleotide pairs used for the cloning and mutagenesis are listed in Supplementary Table S4 .
For SALM3 LRR, the protein expression was verified by transient transfection and western blot detection with goat anti-human polyclonal horse radish peroxidase (HRP) conjugated antibody (Abcam ab98567). A stable Drosophila S2 cell line for SALM3 LRR expression was then generated for the protein purification, and protein was expressed in standard manner as described previously 19 .
The protein with the C-terminal Fc-fusion was affinity purified with protein-A sepharose 
Crystallization and structure determination and refinement
The SALM3 LRR construct was concentrated to 7.2 mg/ml and exchanged to 20 mM Tris pH 7.4, 100 mM NaCl for crystallization. Thin plate-like crystals appeared from 0.17 M ammonium sulfate pH 7.5, 25% w/v PEG 4000, 10% glycerol at +20 °C. Crystals were harvested directly from the drop and flash frozen for data collection. The crystals diffracted to 2.8 Å and crystallized in space group P2 1 , and were twinned (pseudo-orthorhombic) due to the b-angle being almost equal to 90° (Table 1) with high twin-fraction of ca. 34% with the twinning operator h, -k, -l and with two dimers in the asymmetric unit ( Table 1) . The twinning affected the quality of maps and model unavoidably to some extend and complicated the refinement process, however final electron density was of satisfactory quality (Supplementary Fig. S5) .
The SALM3 crystal structure was solved by molecular replacement with the CCP4 package and PHASER 32 . An initial solution for the SALM3 LRR was found using the LRR domain of SALM5 (PDB 6F20) 19 as a template. After molecular replacement and initial refinement with REFMAC 33 , the R-factors for the initial LRR domain model were R work /R free = 41.2%/46.9%. The model was further refined with PHENIX 34 and BUSTER 35 and rebuild with COOT 36 . The final model refined with BUSTER had R-factors of 26.91/28.50% ( Table 1) . Data processing was performed using ScÅtter 37 and DATASW 38 . Particle shapes at low resolution were reconstructed ab initio by DAMMIN 39 in P1 with P(r) function generated from the data truncated to 0.25 ˚A −1 . A total of 10 independent reconstructions were performed, and the models were averaged with the program DAMAVER 40 . Rigid body modeling was performed using CORAL 41 , where available partial crystal structures were treated as rigid bodies while missing residues were modelled as a Cα-chain. The modeling was done with either P1 or P2 symmetry. Porod and dimensionless Kratky plots were calculated for estimation of D max and the overall compactness of the models (Supplementary Fig. S3 ).
Small-angle X-ray scattering data collection and analysis
Homology modeling and conservation analysis
Homology models of SALM3 LRR-Ig and PTPs Ig1-Ig3 structures for SAXS studies and interface analysis were generated based on the known SALM5 (PDB 6F2O) and PTPd crystal structures (PDB 5XNP) using SWISS-MODEL (https://swissmodel.expasy.org/) 42 . Sequence conservation was analysed and plotted on the SALM3 structure using CONSURF 43 TrEMBL or NCBI sequence IDs Q80XU8, Q6PJG9, M3W7N9, H3BGZ7,   B0S5R7 and XP_007909247.1 for SALM3 and Q8BXA0, Q96NI6, A0A337S1F8, H3A0X4, F1Q9H7 and A0A4W3GIX7 for SALM5. The SALM3 LRR-Ig and the PTPs models were superimposed with the SALM5-PTPd complex crystal structure (PDB 5XNP), to generate the initial SALM3-PTPs complex model used as a starting point for SAXS analysis. Multiple sequence alignments were generated with MAFFT 44 .
Cell-based binding assays
We employed the in-cell western blot method 45 to detect the SALM3 and PTPσ interaction on cell surface with the Odyssey Infrared Imaging System (LI-COR Biosciences) following manufacturer's recommendations. In this assay, SALM3 constructs were expressed in HEK293T cells and PTPσ-Fc was added on the cells in a 96-well plate and the binding was detected with antihuman Fc antibody and signal per well was read with the Odyssey Imaging system.
For transfection, HEK293T cells were grown to 90% confluency on a T75 flask using DMEM media with 10% FBS (ThermoFisher) at 37 °C and 5% CO 2 . Cells were seeded into a poly-L lysinecoated 96 well plate at approximately 20 000 cells/well and allowed to grow 24 hours at 37° C until the confluency was 90%. After 24 hours, the cells were transfected with SALM3-pDisplay plasmids (400 µg/well) and polyethylenimine (1.2 µg/well). The transfected cells were incubated at 37 °C for 48 hours. The SALM3 fusion protein expression in transfected cell was detected with Floid TM Cell Imaging system (ThermoFisher) using immunofluorescence.
For immunofluorescence detection, transfected cells were fixed with 4%paraformaldehyde (PFA) for 20 mins and blocked at room temperature with 1xPBS buffer containing 1% BSA for 60 mins, followed by addition of 1:300 dilution primary antibody (rabbit anti-HA, Santa Cruz) and incubation for 30 mins with show shaking at room temperature. The cells were stained with 1:500 dilution secondary antibody (Alexa 488 anti-rabbit, Molecular probes), and the expression was detected with Floid TM Cell Imaging system using green light.
For in-cell western blot experiment, SALM3 transfected HEK293T cells were blocked with EGB buffer 46 
Heterologous synapse-formation assays
HEK293T cells were transfected with the indicated mutants and the WT SALM3 cloned in pDisplay vector (Clontech; listed in Table S4 ). After 48 hours, transfected HEK293T cells were trypsinized, seeded onto cultured hippocampal neurons at DIV9, and then coimmunostained with antibodies against synapsin 47 at DIV11. Images were acquired by confocal microscopy (LSM700, Carl Zeiss). For quantifications, the contours of transfected HEK293T cells were chosen as the ROI.
The fluorescence intensities of synaptic marker puncta, normalized with respect to the area of each HEK293T cell were quantified for both red and green channels using MetaMorph Software (Molecular Devices). All data are expressed as means ± SEM. All experiments were repeated using at least three independent cultures and data were evaluated statistically using a nonparametric Kruskal-Wallis test, followed by Dunn's multiple-comparison test for post hoc groups comparisons (n values used are indicated in the figure legends). Significance was indicated with an asterisk (compared with a value from control group) or hashtag (compared with a value from SALM3 WT-group). cocultured from DIV9 to DIV11 with HEK293T cells expressing the indicated WT-SALM3 protein, its point mutants, or deletion variants. Neurons were then stained with antibodies against HA (blue) and synapsin (red). Scale bar = 10 μm (applies to all images). The synapse-forming activity was quantified by measuring the ratio of synapsin staining intensity (red) to HA immunoreactivity intensity (blue). Data are presented as mean ± SEM (****p < 0.0001 and #### p < 0.0001; n = number of neurons as follows: WT, n = 17; R107S, n = 11; R107S/Q131A, n = 13; R247A, n = 17; L282R, n = 16; L282R/R285A, n = 22; R285A/L305A, n = 17; H313A/L321A, n = 16; T354R/E359A, n = 14;
Figure legends
ΔLRR, n = 17; ΔIg-FNIII, n = 17; and ΔLRR/ΔFNIII, n = 15). Scale bar, 10 μm (applies to all images). 
